{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:03:52Z","timestamp":1794711832459,"version":"4.9.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceuticals Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>This study aimed to compare real-world clinical effectiveness and safety of vedolizumab, an \u03b14\u03b27-integrin inhibitor, and anti-tumour necrosis factor-\u03b1 [anti-TNF\u03b1] agents in biologic-na\u00efve ulcerative colitis [UC] and Crohn\u2019s disease [CD] patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a 24-month retrospective medical chart study in adult UC and CD patients treated with vedolizumab or anti-TNF\u03b1 in Canada, Greece and the USA. Inverse probability weighting was used to account for differences between groups. Primary outcomes were cumulative rates of clinical effectiveness [clinical response, clinical remission, mucosal healing] and incidence rates of serious adverse events [SAEs] and serious infections [SIs]. Secondary outcomes included cumulative rates of treatment persistence [patients who did not discontinue index treatment during follow-up] and dose escalation and incidence rates of disease exacerbations and disease-related surgeries. Adjusted analyses were performed using inverse probability weighting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1095 patients [604 UC, 491 CD] were included. By 24 months, rates of clinical effectiveness were similar between groups, but incidence rates of SAEs (hazard ratio [HR] = 0.42 [0.28\u20130.62]) and SIs (HR = 0.40 [0.19\u20130.85]) were significantly lower in vedolizumab vs anti-TNF\u03b1 patients. Rates of treatment persistence [p &amp;lt; 0.01] by 24 months were higher in vedolizumab patients with UC. Incidence rates of disease exacerbations were lower in vedolizumab patients with UC (HR = 0.58 [0.45\u20130.76]). Other outcomes did not significantly differ between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world setting, first-line biologic therapy in biologic-na\u00efve patients with UC and CD demonstrated that vedolizumab and anti-TNF\u03b1 treatments were equally effective at controlling disease symptoms, but vedolizumab has a more favourable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjab058","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T22:07:28Z","timestamp":1616710048000},"page":"1694-1706","source":"Crossref","is-referenced-by-count":148,"title":["Vedolizumab and Anti-Tumour Necrosis Factor \u03b1 Real-World Outcomes in Biologic-Na\u00efve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study"],"prefix":"10.1093","volume":"15","author":[{"given":"Brian","family":"Bressler","sequence":"first","affiliation":[{"name":"St. Paul\u2019s Hospital, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Yarur","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Bassel","sequence":"additional","affiliation":[{"name":"Evidera, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuelle","family":"Bellaguarda","sequence":"additional","affiliation":[{"name":"Northwestern University \u2013 Feinberg School of Medicine, Evanston, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Fourment","sequence":"additional","affiliation":[{"name":"Texas Digestive Disease Consultants, Southlake, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthie","family":"Gatopoulou","sequence":"additional","affiliation":[{"name":"Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Karatzas","sequence":"additional","affiliation":[{"name":"Laiko General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[{"name":"Sheba Medical Center Ramat Gan and Sackler School of Medicine, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Michalopoulos","sequence":"additional","affiliation":[{"name":"Tzaneion General Hospital of Piraeus, Piraeus, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Michopoulos","sequence":"additional","affiliation":[{"name":"Alexandra Regional General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udayakumar","family":"Navaneethan","sequence":"additional","affiliation":[{"name":"Advent Health, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Siffledeen","sequence":"additional","affiliation":[{"name":"Covenant Health Grey Nuns Community Hospital, Division of Gastroenterology, EdmontonCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Singh","sequence":"additional","affiliation":[{"name":"PerCuro Clinical Research, Victoria, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Soufleris","sequence":"additional","affiliation":[{"name":"Theagenio Anticancer Hospital of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara","family":"Stein","sequence":"additional","affiliation":[{"name":"Evidera, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Demuth","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International \u2013 Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerassimos J","family":"Mantzaris","sequence":"additional","affiliation":[{"name":"Evangelismos Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"2021100708325391000_CIT0001","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"key":"2021100708325391000_CIT0002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ibd.21371","article-title":"Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease","volume":"17","author":"Kappelman","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2021100708325391000_CIT0003","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2165\/00003495-200565160-00002","article-title":"Biologic therapy for inflammatory bowel disease","volume":"65","author":"Ardizzone","year":"2005","journal-title":"Drugs"},{"key":"2021100708325391000_CIT0004","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2021100708325391000_CIT0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","author":"Feagan","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021100708325391000_CIT0006","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2021100708325391000_CIT0007","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/ibd\/izy155","article-title":"Effectiveness and safety of vedolizumab in anti-TNF-na\u00efve patients with inflammatory bowel disease \u2013 a multicenter retrospective European study","volume":"24","author":"Kopylov","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2021100708325391000_CIT0008","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(18)31547-6","article-title":"Comparative effectiveness of vedolizumab and tumor necrosis factor-antagonist therapy in Crohn\u2019s disease: a multicenter consortium propensity score-matched analysis","volume":"154","author":"Bohm","year":"2018","journal-title":"Gastroenterology"},{"key":"2021100708325391000_CIT0009","doi-asserted-by":"crossref","first-page":"otz022","DOI":"10.1093\/crocol\/otz022","article-title":"Comparison","volume":"1","author":"Patel","year":"2019","journal-title":"Crohn\u2019s & Colitis 360"},{"key":"2021100708325391000_CIT0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology"},{"key":"2021100708325391000_CIT0011","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00365521.2017.1304987","article-title":"Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)","volume":"52","author":"Eriksson","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"2021100708325391000_CIT0012","doi-asserted-by":"crossref","first-page":"S1371","DOI":"10.1016\/S0016-5085(18)34477-9","article-title":"Tu2018 \u2013 novel formulation of CT-P13 [infliximab biosimilar] for subcutaneous administration: initial results from a phase I open-label randomized controlled trial in patients with active Crohn\u2019s disease","volume":"154","author":"Schreiber","year":"2018","journal-title":"Gastroenterology"},{"key":"2021100708325391000_CIT0013","article-title":"Treatment patterns of vedolizumab and anti-TNF-a use among patients with UC and CD in Germany: a multicenter retrospective chart review.","author":"Ehehalt","year":"2016"},{"key":"2021100708325391000_CIT0014","first-page":"657","article-title":"What to do when biologic agents are not working in inflammatory bowel disease patients","volume":"11","author":"Dalal","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"2021100708325391000_CIT0015","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.14309\/00000434-201810001-00681","article-title":"Failure of vedolizumab as first-line biologic does not decrease response rates of second-line therapy","volume":"113","author":"Ritter","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2021100708325391000_CIT0016","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2021100708325391000_CIT0017","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.clinthera.2018.07.013","article-title":"Treatment patterns and sequencing in patients with inflammatory bowel disease","volume":"40","author":"Brady","year":"2018","journal-title":"Clin Ther"},{"key":"2021100708325391000_CIT0018","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41395-018-0162-0","article-title":"Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium","volume":"113","author":"Narula","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2021100708325391000_CIT0019","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2021100708325391000_CIT0020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"2021100708325391000_CIT0021","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40264-018-00783-1","article-title":"Benefit\u2013risk assessment of vedolizumab in the treatment of Crohn\u2019s disease and ulcerative colitis","volume":"42","author":"Battat","year":"2019","journal-title":"Drug Saf"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjab058\/38827949\/jjab058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/10\/1694\/40516837\/jjab058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/10\/1694\/40516837\/jjab058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T09:10:24Z","timestamp":1633857024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/15\/10\/1694\/6205394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":21,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,3,30]]},"published-print":{"date-parts":[[2021,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab058","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,3,30]]}}}